Home
Clinical Trials
National Survey on Hypertension

National Survey on Hypertension

Last Updated: 2009-07-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

4500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-12-31

Study Completion Date

2009-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female aged 75 years or older
* With a diagnosis of Hypertension treated or not, seen in general practitioner consultation
* Who has given his/her consent to participate to the study.

Exclusion Criteria

* Patient who participated to a clinical trial

Minimum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

AstraZeneca Pharmaceuticals

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Alain Castaigne, Medical Director

Role: STUDY_DIRECTOR

AstraZeneca

Review additional registry numbers or institutional identifiers associated with this trial.

NIS-CFR-DUM-2008/1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Korean Registry of Target Organ Damages in Hypertension

NCT01861080 UNKNOWN

Intensification of Blood Pressure Lowering Therapeutics Based on Diuretics Versus Usual Management for Uncontrolled Hypertension IN Patients With Moderate to Severe Chronic Kidney Disease

NCT05732727 RECRUITING PHASE3

Treatment of Hypertension in Primary Care in Spain

NCT00868881 COMPLETED

Registry of Arterial Hypertension

NCT04160533 UNKNOWN

Predictive Values of Blood Pressure and Arterial Stiffness in Institutionalized Very Aged Population

NCT00901355 COMPLETED

Systemic Arterial Hypertension in Pediatric Age.

NCT06797908 RECRUITING

Analysis of Antihypertensive Treatment Efficacy

NCT00767247 TERMINATED

The Prevalence of Sympathetic Overactivity in Primary Hypertensive Patients.

NCT01295021 COMPLETED

Renal and Systemic Vascular Resistance in Chronic Kidney Disease (CKD)

NCT01380717 COMPLETED PHASE4

From Micro- to Macro-vessels : Water, Salt, Heart and Kidneys

NCT05114291 COMPLETED

A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension

NCT01658657 COMPLETED NA

The Diagnosis and Treatment of Resistant Hypertension, the Prevalence and the Prognosis

NCT01703780 UNKNOWN

Longitudinal Studies of Blood Pressure in the Elderly

NCT00005409 COMPLETED

Active Screening of Arterial Hypertension by Community Outreach Workers in the Cayenne Metropolitan Area to Reduce the Incidence of Cardiovascular Disease

NCT05814068 UNKNOWN NA

Effects of Inhibition of NO-Synthesis on Renal Hemodynamics and Sodium Excretion in Patients With Essential Hypertension and Healthy Controls

NCT00345150 COMPLETED PHASE1

Renin-Angiotensin System Inhibitors and COVID-19

NCT04331574 UNKNOWN

Predisposition and Transition Mechanisms From Arterial Hypertension to Heart Failure

NCT02430805 COMPLETED NA

Hypertension in Patients Hospitalized With COVID-19

NCT04318301 COMPLETED

The Predictive Role of Urinary Proteomics in Blood Pressure Response of Obese Hypertensive Treated With Irbesartan or Eplerenone.

NCT06208072 RECRUITING NA

Hypertensive Treatment and Epidemiological Analyses

NCT00005501 COMPLETED

Cardiovascular and Renal Outcomes of Integrated Management of Blood Pressure and Other Cardiometabolic Risks in Hypertensives

NCT04531124 NOT_YET_RECRUITING

Prevalence of the Hyperventilation Syndrome in Pulmonary Arterial Hypertension

NCT03810443 UNKNOWN NA

RAS Peptide Profiles in Patients With Treatment-resistant Arterial Hypertension

NCT02962778 COMPLETED

Observational Study to Investigate Resistant Hypertension Prevalence in Korean General Hospitals

NCT01753206 COMPLETED

IntErnational Long-term Follow-up Study of Patients With Uncontrolled HyperTensioN

NCT01705080 TERMINATED

National Survey on Hypertension

Study Results

Basic Information

Brief Summary

Related Clinical Trials